HER2 qRT-PCR from FFPE
Thursday 8 December 2011
The availability of drugs targeting the EGFR/HER/erbB signaling pathway has created a need for diagnostics that accurately predict treatment responses.
The selection of patients with HER2-positive breast cancer for treatment with trastuzumab is based on the measurement of HER2 protein expression by immunohistochemistry, or the presence of HER2 gene amplification by fluorescence in situ hybridization (FISH).
Real time PCR is a reliable and cost-effective method for the assessment of ERBB2 status in archival breast cancer samples, compared with FISH. Its introduction in routine diagnostic pathology practice is feasible even if it requires amendments to the current clinical oncology protocols. (#18382352#)
quantitation of HER1 and HER2 total protein and homodimers in FFPE
- VeraTag Assay (#19214113#, #19214112#)
- Quantitative HER2 immunochemistry
Selection of reference genes for normalization of qRT-PCR data derived from FFPE breast tumors. Drury S, Anderson H, Dowsett M. Diagn Mol Pathol. 2009 Jun;18(2):103-7. PMID: #19430294#
Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry. Capizzi E, Gruppioni E, Grigioni AD, Gabusi E, Grassigli A, Grigioni WF, Fiorentino M. Diagn Mol Pathol. 2008 Dec;17(4):220-6. PMID: #18382352#